Young entrepreneurs are building a new Belgian pharmaceutical empire.
With a second acquisition, brothers Louis and Charles Declerck are further expanding their Belgian pharmaceutical platform. After the acquisition of Nutriphyt in 2023, they now announce the acquisition of family business Trenker Laboratoires from Nivelles.
For Erudite.Health, Trenker will act as a catalyst for their ambition to promote the quality of life of people with health conditions. By offering a wide range of complementary, personalized healthcare, they strive to build a scientifically based bridge between self-care and conventional medicine.
Erudite.Health is rooted in the shared passion and expertise of brothers Louis and Charles Declerck for the biomedical world. Louis, doctor and civil engineer, and Charles, bioengineer specialized in cell and gene technology, draw inspiration from their experiences in the family pharmacy in Kortrijk, Allegaert pharmacy. There they saw first-hand the needs of patients and the desire for more autonomy and quality complementary care. The ambition of these young West Flemish entrepreneurs is clear: they strive to build a Belgian family concern and follow a sustainable buy-and-build strategy.
“We want to build something that transcends ourselves and survives. Our ambition is to build a sustainable Belgian pharmaceutical company that scientifically innovates in self-care and prescription care for people with health problems,” says Louis Declerck, founder of Erudite.Health.
Laboratoires Pharmaceutiques Trenker in Nivelles is a Belgian family business that has been producing nutritional supplements for three generations. Trenker is known for their extensive range of products for hair loss, mobility problems and the immune system, among other things, with high-quality ingredients and innovative formulas. They are committed to scientific research and strive for effective solutions that contribute to the well-being of their customers worldwide. The Trenker family remains involved through a minority stake.
The acquisition was expertly supervised by the independent financial consultancy Merodis on the sell side and ACE Law, Finvision and GPMI on the buy side.
